Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04724928 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

Study acronym: EFFORT-MIBC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Oversight, IPDSharingv4
  2. Primary completion date: May 2027 to Dec 31, 2029v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 10 more changesShow less
    • Primary completion date: Feb 1, 2024 to May 2027
    • Primary endpoint revised
    • Study completion date: Feb 1, 2029 to May 2030
    • Start date changed from estimate of Feb 1, 2021 to Apr 29, 2021
    • Interventions: Immunotherapy (Drug), metastasis directed therapy (MDT) (Radiation) to Immunotherapy (Drug), Metastasis directed therapy (MDT) (Radiation), Standard of care (Procedure)
    • Eligibility criteria expanded, about 71 words
    • Secondary endpoints: 2 to 9
    • Study description shortened, about 90 words
    • Study title revised
    • Collaborators expanded, about 4 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.
Trial Details
NCT Number NCT04724928
Lead Sponsor University Hospital, Ghent
Collaborators: Kom Op Tegen Kanker
Conditions
(from sponsor)		 Muscle-Invasive Bladder Carcinoma
Enrollment 156 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov